Results 61 to 70 of about 255,642 (262)

Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement

Patient Preference and Adherence, 2018
Pin Gao,1 Lili You,2 Di Wu,1 Aiping Shi,1 Qing Miao,3 Ujala Rana,4 Dustin Paul Martin,3 Ye Du,1 Gang Zhao,1 Bing Han,1 Chao Zheng,5 Zhimin Fan1 1Department of Breast Surgery, First Hospital of Jilin University, Changchun, Jilin, China; 2Department of ...
Gao P, You L, Wu D, Shi A, Miao Q, Rana U, Martin DP, Du Y, Zhao G, Han B, Zheng C, Fan Z   +11 more
doaj  

Exploring the ER channel protein Sec61: recent advances in pathophysiological significance and novel pharmacological inhibitors

Frontiers in Pharmacology
The Sec61 complex, which is located on the membrane of the mammalian endoplasmic reticulum (ER), serves as a pivotal component of protein transport channels.
Jingxin Xin, Jingxin Xin, Jingxin Xin, Jingxin Xin, Jingxin Xin, Keling Yin, Keling Yin, Keling Yin, Keling Yin, Keling Yin, Shimeng Li, Shimeng Li, Shimeng Li, Shimeng Li, Shimeng Li, Peiyuan Gu, Peiyuan Gu, Peiyuan Gu, Peiyuan Gu, Peiyuan Gu, Shanshan Shao, Shanshan Shao, Shanshan Shao, Shanshan Shao, Shanshan Shao, Shanshan Shao   +25 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Extracellular ATP promotes endocrine resistance in ER+ breast cancer through upregulation of PYGL

Cell Death and Disease
Hormone receptor (HR)–positive breast cancer accounts for approximately 60% of all breast cancer cases, for which endocrine therapy represents the mainstay of treatment; however, the development of therapeutic resistance substantially limits its clinical
Yu-Qing Yu, Xin-Yao Yu, Xiao-Fei Li, Yi-Fan Cheng, Yan-Ting Zhou, Fang Mei, Liang Weng, Xin-Xia Tian   +7 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Solid component tumor doubling time is a prognostic factor in non-small cell lung cancer patients

Journal of Cardiothoracic Surgery, 2019
Background Recently, several reports investigating tumor doubling times (TDTs) in lung cancer have demonstrated that lung cancer patients with shorter TDTs have poor prognoses.
Kentaro Miura, Kazutoshi Hamanaka, Tomonobu Koizumi, Satoshi Kawakami, Nobutaka Kobayashi, Ken-ichi Ito   +5 more
doaj   +1 more source

Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice

FEBS Open Bio, EarlyView.
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda, Satoru Sugimoto, Chiharu Cho, Madoka Konishi, Nozomi Inoue, Satoshi Miyagaki, Yasuhiro Kawabe, Takuro Okamura, Masahide Hamaguchi, Hisakazu Nakajima, Michiaki Fukui, Masakazu Shinohara, Tomoko Iehara   +12 more
wiley   +1 more source